Next Treatments
Back to Eczema

OpSCF

TypeInjection StagePhase 2 Latest updateUpdated recently. Sep 11, 2026Phase 2 results posted

What stands out

  • Monoclonal antibody
  • Injection every 2 or 4 weeks in trials
Derived from NCT06101823 · This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT06101823
Clear or almost clear skinAfter 16 weeks
OpSCF Matching-Placebo24 people
4 in 100
OpSCF 600 mg26 people
39 in 100
02040
+35
more people in 100 reached it on OpSCF than on placebo.
The sponsor’s 90% confidence range is 18 to 51 more (out of 100).
Eczema score (EASI) at least 75% betterAfter 16 weeks
OpSCF Matching-Placebo24 people
50 in 100
OpSCF 600 mg26 people
62 in 100
04080
+12
more people in 100 reached it on OpSCF than on placebo.
The sponsor’s 90% confidence range is 11 fewer to 35 more (out of 100).
Eczema score (EASI) at least 90% betterAfter 16 weeks
OpSCF Matching-Placebo24 people
17 in 100
OpSCF 600 mg26 people
42 in 100
03060
NCT06101823 · Ages 18–75 · Results posted Sep 2026 · This is a summary of trial data for informational purposes only. It is not medical advice.
Trial: NCT06101823
Itch score at least 4 points betterAfter 16 weeks
OpSCF Matching-Placebo21 people
14 in 100
OpSCF 600 mg21 people
19 in 100
01020
+5
more people in 100 reached it on OpSCF than on placebo.
The sponsor’s 90% confidence range is 15 fewer to 24 more (out of 100).
NCT06101823 · Ages 18–75 · Results posted Sep 2026 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is IGA?
  • IGA stands for Investigator Global Assessment.
  • The vIGA-AD was assessed by the principal investigator or sub-investigator using the descriptors that best described the overall appearance of the lesions.As this trial registered it · NCT06101823 (the full definition is there)
What is EASI?
  • The EASI quantifies severity of a participant's AD based on both lesion severity & % of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema [E], induration/papulation[I], excoriation[Ex] & lichenification[L]) was scored separately for each of 4 body regions[head(h), upper extremities(u), trunk(t), lower extremities(l)] on a 4-point scale:0=absent; 1=mild; 2=moderate; 3=severe.As this trial registered it · NCT06101823 (the full definition is there)
What is the itch score?
  • NRS stands for Numeric Rating Scale.
  • PP-NRS is based on the Numeric Rating Scale which was used to assess the level of itch the participant was experiencing. The following question was be asked to participants: "On a scale of 0 to 10, with 0 = "no itch" and 10 = "worst itch imaginable", how would you rate your itch at the worst moment during the previous 24 hours?" Based on the score provided by participant, the PP-NRS score was assigned.As this trial registered it · NCT06101823 (the full definition is there)
Why this trial?

OpSCF has one trial with posted results, and NCT06101823 compared the drug with placebo on a result this page charts.

History

Earliest recorded event: Nov 21, 2023. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Sep 11, 2026Phase 2 results postedPhase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) ClinicalTrials.gov NCT06101823
  • Aug 18, 2025Phase 2 trial completedPhase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) ClinicalTrials.gov NCT06101823
  • Sep 3, 2024Phase 2 main data collectedPhase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) ClinicalTrials.gov NCT06101823
  • Nov 21, 2023Phase 2 trial startedPhase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) ClinicalTrials.gov NCT06101823

Sources

Trials